SLDB May 2024 12.500 call
| Previous Close | 0.6300 |
| Open | 0.6300 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 12.50 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.6300 - 0.6300 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
GlobeNewswireSolid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting
— Presentations to highlight AAV manufacturing and purification improvements, vector biology updates,and a comprehensive non-clinical data overview of the company’s lead SGT-003 program — CHARLESTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present an oral presentation and six posters and at the American Society of Gene and Cell Therapy (ASGCT) 2024 A
- GlobeNewswire
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 38,508 restricted stock units (“RSUs”) to two newly hired employees. The RSUs vest in four equal installments on each one-year anniversary of the applicable employee’s start date until the fourth anniversary of the applicable employee’s start date. Vesting of the
ZacksSolid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
Solid Biosciences' (SLDB) novel gene-therapy candidate, SGT-003, gets FDA's Rare Pediatric Disease Designation for the treatment of Duchenne muscular dystrophy.
